The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria
Open accessAbstract
The objective of this study was to conduct a prospective population pharmacokinetic and pharmacodynamic evaluation of lumefantrine during blinded comparisons of artemether-lumefantrine treatment regimens in uncomplicated multidrug-resistant falciparum malaria. Three combination regimens containing an average adult lumefantrine dose of 1,920 mg over 3 days (four doses) (regimen A) or 2,780 mg over 3 or 5 days (six doses) (regimen B or C, respectively) were given to 266 Thai patients. Detailed observations were obtained for 51 hospitalized adults, and sparse data were collected for 215 patients of all ages in a community setting. The population absorption half-life of lumefantrine was 4.5 h. The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) μg/ml after regimen A, 9.0 (1.1 and 19.8) μg/ml after regimen B, and 8 (1.4 and 17.4) μg/ml after regimen C. During acute malaria, there was marked variability in the fraction of drug absorbed by patients (coefficient of variation, 150%). The fraction increased considerably and variability fell with clinical recovery, largely because food intake was resumed; taking a normal meal close to drug administration increased oral bioavailability by 108% (90% confidence interval, 64 to 164) ( P , 0.0001). The higher-dose regimens (B and C) gave 60 and 100% higher areas under the concentration-time curves (AUC), respectively, and thus longer durations for which plasma lumefantrine concentrations exceeded the putative in vivo MIC of 280 μg/ml (median for regimen B, 252 h; that for regimen C, 298 h; that for regimen A, 204 h [ P , 0.0001]) and higher cure rates. Lumefantrine oral bioavailability is very dependent on food and is consequently poor in acute malaria but improves markedly with recovery. The high cure rates with the two six-dose regimens resulted from increased AUC and increased time at which lumefantrine concentrations were above the in vivo MIC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Nonlinear Mixed Effects Models for Repeated Measures Data
Lindstrom, M. J., & Bates, D. M. (1990) · Biometrics · doi:10.2307/2532087 · Cited by 1,795
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
White, N. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1413 · Cited by 575
Self-citationCardiac effects of antimalarial treatment with halofantrine
Nosten, F. H., ter Kuile, F. O., Luxemburger, C., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92412-m · Cited by 282
Self-citationPreventing antimalarial drug resistance through combinations
White, N. J. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80208-2 · Cited by 259
Self-citationEzzet, F., Mull, R., & Karbwang, J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00830.x · Cited by 219
Self-citationVugt, M. V., Wilairatana, P., Gemperli, B., Gathmann, I., Phaipun, L., Brockman, A., Luxemburger, C., White, N. J., Nosten, F., & Looareesuwan, S. (1999) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1999.60.936 · Cited by 194
Self-citationvan Vugt, M., Brockman, A., Gemperli, B., Luxemburger, C., Gathmann, I., Royce, C., Slight, T., Looareesuwan, S., White, N. J., & Nosten, F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.135 · Cited by 170
Self-citationHalofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria
ter Kuile, F. O., Nosten, F., Chongsuphajaisiddhi, T., White, N. J., Dolan, G., Luxemburger, C., Phaipun, L., Edstein, M. D., & Webster, H. K. (1993) · The Lancet · doi:10.1016/0140-6736(93)92409-m · Cited by 160
Self-citationPharmacokinetics of halofantrine in man: effects of food and dose size.
Milton, K. A., Edwards, G., Ward, S. A., Orme, M., & Breckenridge, A. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03507.x · Cited by 156
Cited by
Lindenberg, M., Kopp, S., & Dressman, J. B. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.001 · Cited by 864
Medical need, scientific opportunity and the drive for antimalarial drugs
Ridley, R. G. (2002) · Nature · doi:10.1038/415686a · Cited by 789
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
Eastman, R. T., & Fidock, D. A. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2239 · Cited by 568
WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group (2015) · BMC Medicine · doi:10.1186/s12916-015-0456-7 · Cited by 464
Zurovac, D., Sudoi, R. K., Akhwale, W. S., Ndiritu, M., Hamer, D. H., Rowe, A. K., & Snow, R. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60783-6 · Cited by 403
Price, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317
Self-citationVenkatesan, M., Gadalla, N. B., Stepniewska, K., Dahal, P., Nsanzabana, C., Moriera, C., Price, R. N., Mårtensson, A., Rosenthal, P. J., Dorsey, G., et al. (2014) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0031 · Cited by 285
Self-citationRatcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60160-3 · Cited by 271
McGready, R., Stepniewska, K., Lindegardh, N., Ashley, E. A., La, Y., Singhasivanon, P., White, N. J., & Nosten, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0199-7 · Cited by 115
Self-citationTarning, J., McGready, R., Lindegardh, N., Ashley, E. A., Pimanpanarak, M., Kamanikom, B., Annerberg, A., Day, N. P. J., Stepniewska, K., Singhasivanon, P., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-09 · Cited by 99
Self-citationGetawen, S. K., Ashine, T., Massebo, F., Woldeyes, D., & Lindtjørn, B. (2018) · Acta Tropica · doi:10.1016/j.actatropica.2018.02.009 · Cited by 68
Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-141 · Cited by 62
Rahman, M. M., Dondorp, A. M., Day, N. P. J., Lindegardh, N., Imwong, M., Faiz, M. A., Bangali, A. M., Kamal, A. T. M. M., Karim, J., Kaewkungwal, J., et al. (2008) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2008.05.022 · Cited by 54
Bruxvoort, K., Festo, C., Cairns, M., Kalolella, A., Mayaya, F., Kachur, S. P., Schellenberg, D., & Goodman, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134275 · Cited by 37
Abdulla, S., Amuri, B., Kabanywanyi, A. M., Ubben, D., Reynolds, C., Pascoe, S., Fitoussi, S., Yeh, C.-M., Nuortti, M., Séchaud, R., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-253 · Cited by 34
Metadata
- Authors
- Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S., & White, N. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-03
- Volume
- 44
- Issue
- 3
- Pages
- 697-704
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2039639971
- Cited by
- 354
- References
- 16
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.